Investigational Drug Information for Islatravir
✉ Email this page to a colleague
What is the development status for investigational drug Islatravir?
Islatravir is an investigational drug.
There have been 23 clinical trials for Islatravir.
The most recent clinical trial was a Phase 1 trial, which was initiated on February 18th 2020.
The most common disease conditions in clinical trials are HIV Infections, Infections, and Infection. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Merck Sharp & Dohme LLC, and Gilead Sciences.
There are seven US patents protecting this investigational drug and two hundred and seventy-six international patents.
Summary for Islatravir
| US Patents | 7 |
| International Patents | 276 |
| US Patent Applications | 202 |
| WIPO Patent Applications | 105 |
| Japanese Patent Applications | 16 |
| Clinical Trial Progress | Phase 1 (2020-02-18) |
| Vendors | 34 |
Recent Clinical Trials for Islatravir
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) | Merck Sharp & Dohme LLC | Phase 3 |
| DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) | Merck Sharp & Dohme LLC | Phase 3 |
| A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) | Merck Sharp & Dohme LLC | Phase 3 |
Clinical Trial Summary for Islatravir
Top disease conditions for Islatravir
Top clinical trial sponsors for Islatravir
US Patents for Islatravir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Islatravir | ⤷ Sign Up | Therapeutic compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Islatravir | ⤷ Sign Up | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (Tokyo, JP) | ⤷ Sign Up |
| Islatravir | ⤷ Sign Up | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof | ⤷ Sign Up | |
| Islatravir | ⤷ Sign Up | Antiviral prodrugs of tenofovir | Merck Sharp & Dohme Corp. (Rahway, NJ) Idenix Pharmaceuticals LLC. (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Islatravir
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Islatravir | Argentina | AR109364 | 2036-08-19 | ⤷ Sign Up |
| Islatravir | Argentina | AR115865 | 2036-08-19 | ⤷ Sign Up |
| Islatravir | Argentina | AR117709 | 2036-08-19 | ⤷ Sign Up |
| Islatravir | Australia | AU2017312102 | 2036-08-19 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
